These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37283978)

  • 21. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research.
    Newman SK; Jayanthan RK; Mitchell GW; Carreras Tartak JA; Croglio MP; Suarez A; Liu AY; Razzo BM; Oyeniran E; Ruth JR; Fajgenbaum DC
    Yale J Biol Med; 2015 Dec; 88(4):383-8. PubMed ID: 26604862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.
    Srkalovic G; Marijanovic I; Srkalovic MB; Fajgenbaum DC
    Bosn J Basic Med Sci; 2017 May; 17(2):81-84. PubMed ID: 28135567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.
    Liu W; Cai Q; Yu T; Strati P; Hagemeister FB; Zhai Q; Zhang M; Li L; Fang X; Li J; Sun R; Zhang S; Yang H; Wang Z; Qian W; Iwaki N; Sato Y; Oksenhendler E; Xu-Monette ZY; Young KH; Yu L
    Am J Cancer Res; 2022; 12(9):4227-4240. PubMed ID: 36225639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The full spectrum of Castleman disease: 273 patients studied over 20 years.
    Oksenhendler E; Boutboul D; Fajgenbaum D; Mirouse A; Fieschi C; Malphettes M; Vercellino L; Meignin V; Gérard L; Galicier L
    Br J Haematol; 2018 Jan; 180(2):206-216. PubMed ID: 29143319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Advances in Castleman Disease.
    Hoffmann C; Hentrich M; Tiemann M; Rosenwald A; Weber F; Willenbacher W; Hübel K
    Oncol Res Treat; 2022; 45(11):693-704. PubMed ID: 36219975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Not Available].
    Bertinchamp R; Terriou L
    Rev Med Interne; 2022 Dec; 43(10S1):10S4-10S9. PubMed ID: 36657941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease.
    Butzmann A; Kumar J; Sridhar K; Gollapudi S; Ohgami RS
    Biology (Basel); 2021 Mar; 10(4):. PubMed ID: 33804823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological comparison and therapeutic approach to Castleman disease-a case-based review.
    Wojtyś M; Piekarska A; Kunc M; Ptaszyński K; Biernat W; Zaucha JM; Waloszczyk P; Lisowski P; Kubisa B; Grodzki T
    J Thorac Dis; 2019 Nov; 11(11):4859-4874. PubMed ID: 31903277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative analysis of a rare disease network's international contact database and E-repository provides insights into biobanking in the electronic consent era.
    Suarez A; Reilly C; Fajgenbaum DC
    Orphanet J Rare Dis; 2019 Jul; 14(1):173. PubMed ID: 31296233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The French paediatric cohort of Castleman disease: a retrospective report of 23 patients.
    Borocco C; Ballot-Schmit C; Ackermann O; Aladjidi N; Delaleu J; Giacobbi-Milet V; Jannier S; Jeziorski E; Maurier F; Perel Y; Piguet C; Oksenhendler E; Koné-Paut I; Galeotti C
    Orphanet J Rare Dis; 2020 Apr; 15(1):95. PubMed ID: 32303241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Castleman Disease: A Multicenter Case Series from Turkey.
    Gündüz E; Kırkızlar HO; Ümit EG; Karaman Gülsaran S; Özkocaman V; Özkalemkaş F; Candar Ö; Elverdi T; Küçükyurt S; Paydaş S; Çeneli Ö; Karakuş S; Maral S; Ekinci Ö; İpek Y; Kis C; Güven ZT; Akdeniz A; Celkan T; Eroğlu Küçükdiler AH; Akgün Çağlıyan G; Özçelik Şengöz C; Karataş A; Bulduk T; Özcan A; Belen Apak FB; Canbolat A; Kartal İ; Ören H; Töret E; Özdemir GN; Bakanay Öztürk ŞM
    Turk J Haematol; 2022 Jun; 39(2):130-135. PubMed ID: 35176839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.
    Yu L; Shi M; Cai Q; Strati P; Hagemeister F; Zhai Q; Li L; Fang X; Li J; Sun R; Zhang S; Yang H; Wang Z; Qian W; Iwaki N; Sato Y; Zhang L; Li J; Oksenhendler E; Xu-Monette ZY; Young KH
    Oncologist; 2020 Nov; 25(11):963-973. PubMed ID: 32852137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology of Castleman Disease.
    Simpson D
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):1-10. PubMed ID: 29157611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease.
    Horna P; King RL; Jevremovic D; Fajgenbaum DC; Dispenzieri A
    Haematologica; 2023 Jan; 108(1):207-218. PubMed ID: 35484648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
    van Rhee F; Voorhees P; Dispenzieri A; Fosså A; Srkalovic G; Ide M; Munshi N; Schey S; Streetly M; Pierson SK; Partridge HL; Mukherjee S; Shilling D; Stone K; Greenway A; Ruth J; Lechowicz MJ; Chandrakasan S; Jayanthan R; Jaffe ES; Leitch H; Pemmaraju N; Chadburn A; Lim MS; Elenitoba-Johnson KS; Krymskaya V; Goodman A; Hoffmann C; Zinzani PL; Ferrero S; Terriou L; Sato Y; Simpson D; Wong R; Rossi JF; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Oksenhendler E; Fajgenbaum DC
    Blood; 2018 Nov; 132(20):2115-2124. PubMed ID: 30181172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are Patients with HHV-8 Associated Castleman Disease Successfully Treated with Rituximab at Risk of Subsequently Developing HHV-8 Negative (Idiopathic) Castleman Disease?
    Ha G; Kwong K; Tanaka B; Nishimura Y; Chong C
    Eur J Case Rep Intern Med; 2023; 10(7):003904. PubMed ID: 37455698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease].
    Okamoto S
    Rinsho Ketsueki; 2019; 60(9):1205-1211. PubMed ID: 31597845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical features and treatment outcomes of Castleman disease in children: a retrospective cohort in China.
    Hu S; Li Z; Wang H; Chen L; Ma Y; Zhu X; Li J; Dong R; Yao W; Dong C; Zhang H; Li K; Dong K; Zhai X
    Eur J Pediatr; 2023 Dec; 182(12):5519-5530. PubMed ID: 37782352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.